Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| FRE | Ann: Disclosure Notice - D&O Relevant Interests | 05/04/18 | 0 | 22 | |||
|
|||||||
| FRE | Ann: FRE - Half Year Report for the 6 months ended 31 Dec 2017 | 26/03/18 | 0 | 29 | |||
|
|||||||
See All Discussions
NZX News